No Data
No Data
European Equities Traded in the US as American Depositary Receipts Move Slightly Higher in Thursday Trading
Ascendis Pharma Ticks Higher Amid Report It Cancelled From Upcoming Conference
MBX Bio Drops Despite Bullish Views on Street
Septerna, Hypoparathyroidism Drug Developer, Files for $100M IPO
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug
Express News | Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism